Locust Walk Market Conditions CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Multitrack Process Negotiation Partnering Quarterly Reports ARCHIVE 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 LOCUST WALK INSIGHTS 2025 Q3 Report: Global Trends in Biopharma Transactions October 8, 2025 2025 Q2 Report: Global Trends in Biopharma Transactions July 10, 2025 2025 Q1 Report: Global Trends in Biopharma Transactions April 11, 2025 2024 Year-In-Review Report: Global Trends in Biopharma Transactions January 11, 2025 2023 Year-In-Review Report: Global Trends in Biopharma Transactions January 6, 2024 2022 Year In Review Report: Global Trends in Biopharma Transactions January 8, 2023 2021 Year End Report January 10, 2022 Locust Walk 2020 Year End Report January 28, 2021 2019 Year End Review Biopharma Report January 11, 2020 2019 Medtech Year End Review Report January 11, 2020 Global Business Reports Interview with Geoff Meyerson, CEO & Co-Founder of Locust Walk May 6, 2019 Executing a successful buy-side transaction for commercial stage companies April 12, 2017 Deal Strategy and Objectives March 29, 2017 Life is Long, Don’t Give Up March 23, 2017 The Potential Impact of FDA Leadership Changes on Drug Partnership March 15, 2017 What happened to the value of priority review vouchers (PRV)? March 2, 2017 Immunomedics and venBio: Activist Investors in Biotech February 22, 2017 The Uneven Pendulum: Measuring Upside and Downside in Biopharma Stock Performance February 15, 2017 How to Get Deal Experience Without Having Deal Experience January 25, 2017 Japan Licensing Deals: A look back at 2016, and what to expect in 2017 January 18, 2017 Business Development Implications of the 21st Century Cures Act December 14, 2016 The Case for Europe. December 7, 2016 Immuno-Oncology Deals: Why Are They So Hot? December 1, 2016 A bird in the hand is worth two in the bush. November 22, 2016 New Horizons of the Regenerative Medicine Space in Japan November 15, 2016 Implications of the US election on the Life Science Industry November 9, 2016 Maximizing Buy Side Success as a Smaller Company November 2, 2016 Creating an Event Horizon for Your Deal October 28, 2016 Why medical device companies can benefit from a commercial assessment early on? October 20, 2016 Business Development Confidential: Using CDAs and Data Rooms to Structure a Transaction Process October 14, 2016 The Art of the Life Sciences Deal October 6, 2016 How to Survive the Biotech Roller Coaster Ride September 28, 2016 Stock vs. Asset Purchase Agreements: One Word Can Make a World of Difference September 21, 2016 The Improving Japanese Pharmaceutical Regulatory Environment September 14, 2016 Geoff Meyerson – The Business of Convergence by Stacey Alcorn September 8, 2016 Best Practices to Effectively Manage Due Diligence September 8, 2016 Best Practices to Prepare for a Sell-Side Process September 1, 2016 Three Main Factors to Focus on When Valuing an Asset August 25, 2016 Q2 2016 Trends in Biotech Finance August 1, 2016 How to Approach Regional Partnering Deals in Japan and Asia July 25, 2016 The Value of A Commercial Assessment in Supporting a Transaction July 14, 2016 Partnering Your Drug – To Provide Deal Terms Guidance or Not July 7, 2016 Brexit’s Impact on Development Stage Biopharma June 29, 2016 Locust Walk’s Japanese Presence Expedites Licensing Agreement for Client Medgenics June 21, 2016 Recap of Spring 2016 Locust Walk Institute: Financing your biotech from idea to IPO May 11, 2016 Advantages of Running a Multitrack Process April 14, 2016 How to Finance a Commercial Product Acquisition April 12, 2016 Eat Or Be Eaten: Controlling Your Fate In The Specialty Pharma MA Feeding Frenzy July 23, 2015 Building value through regional licensing; global dealmakers get guidance on Japan May 12, 2015
